About us
Amazing biological discoveries made by young scientists change the world.
We develop bioelectronic medicine for preventing and treating the age-related diseases.
The goal of our research is to help people get rid of pain and enrich the quality of their lives.
Who We Are
In 2013, a team of young scientists studying chemistry, biology and computer engineering at the University of Illinois discovered a treatment protocol that rapidly increases the heart rate variability by using mild electromagnetic signals during a bioelectromagnetics experiment. In the additional clinical studies, the team identified the possibility to restore the balance of the autonomic nervous system and treat age-related chronic diseases.
In 2016, AMO Lab was established as a bioelectronics company in the United States and Korea based on its proprietary neurostimulation platform.
Our Mission
Age-related chronic diseases cause significant economic, personal and social burdens for individuals, families and communities.
Our mission is to delay, halt or even reverse aging, which is the ultimate goal of humanity, with natural, safe therapies without any side effect.
Our Mission
Age-related chronic diseases cause significant economic, personal and social burdens for individuals, families and communities.
Our mission is to delay, halt or even reverse aging, which is the ultimate goal of humanity, with natural, safe therapies without any side effect.
Non-Contact Bioelectronic Device
AMO+, the first commercial product of AMO Lab, is a consumer wellness product that improves the quality of sleep through a unique non-invasive, contact-free approach for vagus nerve stimulation.
This innovative wearable sleep device has been completed as a result of persistent commitment and clinical studies of young scientists with their vision for the future of bioelectronics.
Contact-free Bioelectronic Medicine
AMO+, the first commercial product of AMO Lab, is a consumer wellness product that improves the quality of sleep through a unique non-invasive, contact-free approach for vagus nerve stimulation.
This innovative wearable sleep device has been completed as a result of persistent commitment and clinical studies of young scientists with their vision for the future of bioelectronics.
Our Funding
We attracted three funding from NAVER D2SF, NEOPLY, and SEOIL E&M in Korea. In 2022, we will announce a financing of over $10 million in a Series A funding round from venture capitals.
Our Funding
We attracted two seed funding from NAVER D2SF and NEOPLY in Korea. In 2019, we will announce a financing of over $10 million in a Series A funding round from venture capitals.
Our Intellectual Property
We have broad portfolio of intellectual property rights of seven patents applied and registered globally. The patent covers signal processing, treatment methods and non-invasive delivery methods and contains a portion of the critical areas of our technology.
Our Intellectual Property
We have broad portfolio of intellectual property rights of seven pending patents globally. The patent covers signal processing, treatment methods and noninvasive delivery methods and contains a portion of the critical areas of our technology.
Our History
2019
Product demonstration at CES 2019
2nd clinical trial (ISI/PSQI)
Published academic paper in AHFE 2019
3rd clinical trial (ECG/EEG/Melatonin)
2018
1st clinical trial (ECG)
2017
Proof-of-concept of cervicothoracic vagus electromagnetic stimulation (cVES)
2016
Incorporation in South Korea and U.S.
2015
Completed first electromagnetic stimulator
2013
Design & Prototyping
2012
Research begins on Bioelectronics
2020
Published academic paper in AHFE 2020
Wadiz crowdfunding campaign
Launched sleep device AMO+
2021
Indiegogo campaign of ‘amofit S’ Nov
First Batch of Manufacturing & Shipping begins (4,000 products) Dec
2022
Jan Second Batch of Manufacturing
Our Partnership
Medical Institutions
Medical Advisor
Korea Government Agency
Investors
